Rilonacept

Phase 1UNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autoimmune Neurosensory Hearing Loss (ANSHL)

Conditions

Autoimmune Neurosensory Hearing Loss (ANSHL)

Trial Timeline

Feb 1, 2017 → Mar 1, 2018

NCT ID

NCT02828033

About Rilonacept

Rilonacept is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Autoimmune Neurosensory Hearing Loss (ANSHL). The current trial status is unknown. This product is registered under clinical trial identifier NCT02828033. Target conditions include Autoimmune Neurosensory Hearing Loss (ANSHL).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00609544	Phase 2	Withdrawn	—	—	Chronic Kidney Disease
NCT02828033	Phase 1	UNKNOWN	Feb 1, 2017	Mar 1, 2018	Autoimmune Neurosensory Hearing Loss (ANSHL)
NCT01538719	Phase 1/2	Completed	Dec 1, 2011	Aug 11, 2017	Scleroderma
NCT00856206	Phase 3	Completed	Mar 1, 2009	Jan 1, 2011	Gout
NCT00610363	Phase 2	Completed	Nov 1, 2007	Oct 1, 2008	Gout

Competing Products

20 competing products in Autoimmune Neurosensory Hearing Loss (ANSHL)

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	77
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	52
Enteric-coated Mycophenolate Sodium	Novartis	Phase 3	77
Ianalumab + Placebo	Novartis	Phase 3	77
VAY736	Novartis	Phase 2/3	65
remibrutinib	Novartis	Phase 1	33
RO7049665	Roche	Phase 2	52
rituximab (Mabthera®) + Placebo	Roche	Phase 3	77
NovoMix 30 + Tablet treatment	Novo Nordisk	Pre-clinical	22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)	Swedish Orphan Biovitrum	Phase 2	51
branebrutinib + abatacept + branebrutinib placebo	Bristol Myers Squibb	Phase 2	51
BMS-986165	Bristol Myers Squibb	Phase 1	32
Nivolumab	Bristol Myers Squibb	Phase 1	32
Fludarabine + Cyclophosphamide + Tocilizumab	Bristol Myers Squibb	Phase 1	32
BMS-986165 + Rosuvastatin	Bristol Myers Squibb	Phase 1	32
SAR445088	Sanofi	Phase 1	32
BIVV020	Sanofi	Phase 1	32
rilzabrutinib	Sanofi	Phase 2	51

Other Products from Regeneron Pharmaceuticals

DupilumabApproved

Intravitreal Aflibercept Injection 2mgApproved

Intravitreal aflibercept injection 2.0mgApproved

PozelimabApproved

DupilumabApproved